GlassScriptPhysician profile
Jean-Baptiste Pierre
NPI 1235500844
$5,118.12
in general payments reported to CMS, 2019-2025
29 companies · $1,064 in 2025
The $1,064 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $458 · 2022: $957 · 2023: $1,358 · 2024: $1,282 · 2025: $1,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,703.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $844.84 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $767.07 | 2021-2024 | Xarelto |
| Abbvie INC. | $588.73 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $468.83 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $444.30 | 2022-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $320.13 | 2021-2025 | |
| Amgen INC. | $208.33 | 2023-2024 | Repatha, Otezla |
| Astellas Pharma US INC | $190.23 | 2021-2025 | Veozah |
| Novo Nordisk INC | $167.96 | 2021-2025 | Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $130.00 | 2025 | Caplyta |
| Abbott Laboratories | $124.99 | 2023 | Freestyle Libre 3 |
| Lilly USA, LLC | $107.96 | 2021-2024 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $106.47 | 2021-2022 | |
| Shield Therapeutics INC | $100.50 | 2022-2024 | Accrufer |
| Janssen Biotech, INC. | $86.19 | 2025 | Rybrevant, Carvykti |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $85.30 | 2021-2025 | |
| Exact Sciences Corporation | $73.74 | 2023-2025 | Cologuard Collection Kit |
| Agios Pharmaceuticals, INC. | $43.94 | 2025 | Pyrukynd |
| Almatica Pharma LLC | $41.42 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.50 | 2021-2024 | |
| Kowa Pharmaceuticals America, INC. | $30.12 | 2021-2023 | Seglentis |
| Amarin Pharma, INC. | $26.85 | 2021 | |
| Sumitomo Pharma America, INC. | $21.67 | 2025 | Gemtesa |
| Actelion Pharmaceuticals US, INC. | $19.10 | 2023 | Uptravi, Opsumit |
| Novartis Pharmaceuticals Corporation | $18.38 | 2023 | |
| Ibsa Pharma INC. | $17.08 | 2023 | Tirosint, Licart |
| Dexcom, INC. | $15.65 | 2025 | Dexcom G6 Transmitter |
| Seqirus USA INC | $15.43 | 2025 | Flucelvax, Fluad |
| Alvogen INC | $15.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean-Baptiste Pierre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.